A. Poletti, University of Milan

Condividi su
Data dell'evento: 11/09/2015
milano_torino_2

Friday, 11th September 2015 - h 14:00
Seminars Room, NICO

The protein quality control system in motoneuron diseases
Angelo Poletti
Dipartimento di Scienze Farmacologiche e Biomolecolari Università di Milano

Motor neuron diseases, like spinobulbar muscular atrophy (SBMA) and amyotrophic lateral sclerosis (ALS) are characterized by the presence of inclusions or aggregates of proteinaceous materials. This is due to the generation of aberrant conformations (misfolding) of the proteins responsible for the diseases.

In neuronal cells, the protein quality control (PQC) system may be insufficient to correctly remove the misfolded proteins.
The PQC system requires the activities of efficient chaperones and of the degradative systems ubiquitin-proteasome (UPS) and autophagy. Our approaches are to better characterize the role of the PQC in motoneuron diseases and to find possible ways to boost the PQC activity in order to prevent the damages induced by misfolded proteins to neurons.

Ospite: Alessandro Vercelli

Agenda

06 novembre 2018

ZEISS Academy Workshop – Microscopia Correlativa 3D

Le ultime novità nella Microscopia Correlativa Multi-modale. Registrazione obbligatoria.

16 febbraio 2019

Torino - 10th International Meeting STEROIDS and NERVOUS SYSTEM

Since 2001, this meeting represented an important event for basic and clinical researchers working on this emerging scientific topic. We will address state-of-the-art approaches in the field of steroids and nervous system, including behavior, epigenetics, genomic and non-genomic actions, the vitamin D, neurodegenerative and psychiatric disorders, and the interference among endocrine disruptors and steroid signaling.

Ricerca

Identificato un nuovo bersaglio per contrastare la SMA

L’inibizione della proteina JNK rallenta la progressione della malattia che colpisce i motoneuroni ed è la prima causa genetica di morte nell’infanzia. Lo dimostra uno studio pubblicato su Frontiers in Molecular Neuroscience dal nostro gruppo di ricerca guidato da Alessandro Vercelli, in collaborazione con l’Istituto Mario Negri di Milano. Chiarire i meccanismi molecolari alla base della SMA può aprire la strada allo sviluppo di nuove terapie.

24 ottobre 2018